[go: up one dir, main page]

BR0015539A - Adamantil e noradamantil aril- e aralquilpiperazinas ramificadas com atividade 5-ht1a de serotonina - Google Patents

Adamantil e noradamantil aril- e aralquilpiperazinas ramificadas com atividade 5-ht1a de serotonina

Info

Publication number
BR0015539A
BR0015539A BR0015539-0A BR0015539A BR0015539A BR 0015539 A BR0015539 A BR 0015539A BR 0015539 A BR0015539 A BR 0015539A BR 0015539 A BR0015539 A BR 0015539A
Authority
BR
Brazil
Prior art keywords
disease
branched
ischemia
aryl
compounds
Prior art date
Application number
BR0015539-0A
Other languages
English (en)
Inventor
Wayne Everett Childers Jr
Horace Flecher Iii
Magib Abdel-Megib Abou-Gharbia
John Patrick Yardley
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Priority claimed from US09/706,683 external-priority patent/US6831084B1/en
Publication of BR0015539A publication Critical patent/BR0015539A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)

Abstract

"ADAMANTIL E NORADAMANTIL ARIL E ARALQUILPIPERAZINAS RAMIFICADAS COM ATIVIDADE 5-HT~ 1A~ DE SEROTONINA". A invenção refere-se compostos e métodos usando-os para prover neuroproteção e prevenir ou limitar processos de neurodegeneração em mamíferos incluindo Doença de Alzheimer, Doença de Huntington, Doença de Parkison, demência da AIDS, doença da retina, neuropatia periférica diabética, esclerose múltipla, derrame, derrame tromboembólico agudo, isquemia focal, isquemia global, ataque isquêmico transitório, isquemia resultante de cirurgia, trauma craniano, trauma espinhal, hipoxia, hipoxia fetal e neuroproteção; os compostos tendo a estrutura (1), em que X é -CH~ 2~- ou uma ligação; Y é -(CH~ 2~)m~- ou -(CH~ 2~)-O-(CH~ 2~)-; m é 0 ou 1; n é 0 ou 1; R~ 1~e R~ 2~ são independentemente selecionados de arila ou heteroarila opcionalmente substituída; os seus isómeros ópticos e sais farmaceuticamente aceitáveis.
BR0015539-0A 1999-11-12 2000-11-06 Adamantil e noradamantil aril- e aralquilpiperazinas ramificadas com atividade 5-ht1a de serotonina BR0015539A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22882099P 1999-11-12 1999-11-12
US43979899A 1999-11-12 1999-11-12
US21934899P 1999-11-18 1999-11-18
US44298199A 1999-11-18 1999-11-18
PCT/US2000/030529 WO2001034586A2 (en) 1999-11-12 2000-11-06 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a activity
US09/706,683 US6831084B1 (en) 1999-11-12 2000-11-06 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity
US10/783,109 US6828324B2 (en) 1999-11-12 2004-02-20 Branched adamantyl and noradamantyl aryl-and aralkylpiperazines with serotonin 5-HT1A activity

Publications (1)

Publication Number Publication Date
BR0015539A true BR0015539A (pt) 2002-07-16

Family

ID=34468557

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015539-0A BR0015539A (pt) 1999-11-12 2000-11-06 Adamantil e noradamantil aril- e aralquilpiperazinas ramificadas com atividade 5-ht1a de serotonina

Country Status (9)

Country Link
US (1) US6828324B2 (pt)
EP (1) EP1276731A2 (pt)
JP (1) JP2003517468A (pt)
CN (1) CN1507437A (pt)
AU (1) AU1468001A (pt)
BR (1) BR0015539A (pt)
CA (1) CA2390524A1 (pt)
WO (1) WO2001034586A2 (pt)
ZA (1) ZA200204683B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
CA2417960C (en) 2000-08-04 2012-07-10 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
WO2002102988A2 (en) * 2001-06-18 2002-12-27 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
US7115607B2 (en) * 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
CN103191409A (zh) 2003-05-15 2013-07-10 Dmi生物科学公司 T-细胞介导的疾病的治疗
ATE520421T1 (de) * 2005-02-02 2011-09-15 Mallinckrodt Inc Radioaktiv markierte brückenkopf-verbindungen und verfahren zu ihrer verwendung
US20100227934A1 (en) * 2007-06-15 2010-09-09 University Of Florida Research Foundation, Inc Therapeutic compounds and methods of use
US8354382B2 (en) 2008-04-16 2013-01-15 Kissei Pharmaceutical Co., Ltd. Hemifumarate of a pyrazole derivative
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
JP2013537195A (ja) 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション 疾患の治療
PL2766029T3 (pl) 2011-10-10 2020-08-24 Ampio Pharmaceuticals, Inc. Leczenie choroby zwyrodnieniowej stawów
PH12014500686A1 (en) 2011-10-10 2020-12-18 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
US10881710B2 (en) 2011-10-28 2021-01-05 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
KR20170045274A (ko) 2014-08-18 2017-04-26 앰피오 파마슈티컬스 인코퍼레이티드 관절 징후의 치료
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US4001223A (en) 1975-01-13 1977-01-04 Idemitsu Kosan Co., Ltd. Adamantane-piperazine derivatives
US4202898A (en) 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
US4797489A (en) 1987-12-02 1989-01-10 American Home Products Corp. Adamantyl- and fluorenyl-arylpiperazines and -arylpiperidines
IL90279A (en) 1988-05-24 1995-03-30 American Home Prod History of piperazinyl carboxamide, their preparation and the pharmaceutical preparations containing them
US5254552A (en) 1988-05-24 1993-10-19 American Home Products Corporation Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity
US5482940A (en) 1988-05-24 1996-01-09 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
US4873331A (en) 1988-12-09 1989-10-10 American Home Products Corporation Noradamantyl-carboxylic acid piperazinoalkyl esters
US4882432A (en) 1989-01-09 1989-11-21 American Home Products Corporation Polycyclic-carbamic acid piperazinoalkyl esters and amides
GB8909209D0 (en) 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
KR0173310B1 (ko) * 1989-04-22 1999-02-01 폴 에이 리쳐 피페라진 유도체
US5364849A (en) 1989-04-22 1994-11-15 John Wyeth & Brother, Limited 1-[3 or 4-[1-[4-piperazinyl]]-2 arylpropionyl or butryl]-heterocyclic derivatives
IE64038B1 (en) * 1989-04-22 1995-06-28 Wyeth John & Brother Ltd Tertiary alkyl functionalized piperazine derivatives
US5340812A (en) 1989-04-22 1994-08-23 John Wyeth & Brother, Limited Piperazine derivatives
IL101722A (en) 1991-05-02 1996-05-14 Wyeth John & Brother Ltd History of piperazine, their preparation and pharmaceutical preparations containing them
US5486518A (en) 1995-04-10 1996-01-23 American Home Products Corporation 4-indolylpiperazinyl derivatives
US5519025A (en) 1995-04-10 1996-05-21 American Home Products Corporation 4-indolylpiperazinyl derivatives
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
CN1342152A (zh) * 1999-03-02 2002-03-27 美国家用产品公司 N－取代的具有5－羟色胺能活性的酰亚胺衍生物
AU3247800A (en) * 1999-03-03 2000-09-21 American Home Products Corporation New diazole derivatives as serotonergic agents

Also Published As

Publication number Publication date
US6828324B2 (en) 2004-12-07
US20040162430A1 (en) 2004-08-19
CN1507437A (zh) 2004-06-23
JP2003517468A (ja) 2003-05-27
WO2001034586A3 (en) 2002-11-07
CA2390524A1 (en) 2001-05-17
EP1276731A2 (en) 2003-01-22
WO2001034586A2 (en) 2001-05-17
AU1468001A (en) 2001-06-06
ZA200204683B (en) 2003-10-15

Similar Documents

Publication Publication Date Title
BR0015539A (pt) Adamantil e noradamantil aril- e aralquilpiperazinas ramificadas com atividade 5-ht1a de serotonina
WO2000021487A3 (en) Formoterol polymorphs
ATE229017T1 (de) Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
PT92728A (pt) Processo para a preparacao de derivados de piperazinilo e de composicoes farmaceuticas que os contem
NO20060111L (no) Spesifikke glukokortikosteroid forbindelser med anti- inflammatorisk aktivitetet
BR0116450A (pt) Composto, processos para a preparação de um carbamato, e para produzir um sal, composição farmacêutica, uso de um composto ou de uma composição farmacêutica, e, produto de combinação
WO2001028996A3 (en) Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases
NZ514477A (en) Adamantane derivatives
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
CA2275166A1 (en) Novel benzopyran derivatives
CA2168097A1 (en) Substituted 2-aminotetralins
PT870757E (pt) Derivados de adamantano substituidos por fluoro
BR0011902A (pt) Compostos derivados de ciclopentano substituìdo, respectivos processos de preparação e formas cristalinas
EP0790246A4 (en) POTENTIALIZER OF THE ACTIVITY OF THE NERVOUS GROWTH FACTOR CONTAINING A DERIVATIVE OF 1,2-ETHANEDIOL OR A SALT THEREOF
PT1268407E (pt) Derivados de amidoxima de acido propenocarboxilico, um processo para a sua preparacao e composicoes farmaceuticas contendo os mesmos
JP5345073B2 (ja) 抗ウイルス化合物
FI20001775A (fi) Välituotteina käyttökelpoisia iminosubstituoituja syklopent/b/indolijohdannaisia
EP0945426A4 (en) NITRO DERIVATIVES
DK0664807T3 (da) Quinoxalindionderivater som EAA-antagonister
CA2119782A1 (en) Carbamate analogs of thiaphysovenine, pharmaceutical compositions, and method for inhibiting cholinesterases
CA2300289A1 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
MXPA02004655A (es) Adamantilo ramificado y aril-noradamantilo y aralquilpiperazinas con actividad de serotonina 5-ht1a.
EA199600007A3 (ru) Новые трициклические производные, способ их получения, способы получения оптически активных или рацемических колхицина и тиоколхицина, их аналогов или производных с использованием трициклических соединений и промежуточные продукты синтеза
NO178025C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive (benzhydryloksyetylpiperidyl)alifatiske syrederivater
JPS6466116A (en) Antiemetic containing specific substituted phenylalkylamino and amino acid derivatives and compound selected from other serotonin drying drugs

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007.